{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:48:18Z","timestamp":1773326898075,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["883\/21"],"award-info":[{"award-number":["883\/21"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006544","name":"Ministry of Health, State of Israel","doi-asserted-by":"publisher","award":["3\/15080"],"award-info":[{"award-number":["3\/15080"]}],"id":[{"id":"10.13039\/501100006544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.09.014","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:14:12Z","timestamp":1759342452000},"page":"e132-e140.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced Multicolor Flow Cytometry Method for Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6600-7745","authenticated-orcid":false,"given":"Noa","family":"Ofir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5368-9466","authenticated-orcid":false,"given":"Ety","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omri","family":"Sharabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Zektser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3241-5561","authenticated-orcid":false,"given":"Ory","family":"Rouvio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-2147","authenticated-orcid":false,"given":"Roi","family":"Gazit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.09.014_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.09.014_bib0002","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.clml.2025.09.014_bib0003","first-page":"1","article-title":"Multiple myeloma","volume":"101","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.clml.2025.09.014_bib0004","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How i treat multiple myeloma in geriatric patients","volume":"143","author":"Facon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.014_bib0005","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.014_bib0006","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1038\/bcj.2017.90","article-title":"Current applications of multiparameter flow cytometry in plasma cell disorders","volume":"7","author":"Jelinek","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.09.014_bib0007","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2025.09.014_bib0008","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/diagnostics11091534","article-title":"Clonal evolution of multiple myeloma\u2014clinical and diagnostic implications","volume":"11","author":"Salomon-Perzy\u0144ski","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.clml.2025.09.014_bib0009","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","article-title":"Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.014_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.09.014_bib0011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bjh.14649","article-title":"Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma","volume":"178","author":"Dutta","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.09.014_bib0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.09.014_bib0013","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/j.clml.2023.11.006","article-title":"Multiparametric flow cytometry in the evaluation of plasma cell proliferative disorders: current paradigms for clinical practice","volume":"24","author":"Gupta","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.09.014_bib0014","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.09.014_bib0015","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2025.09.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89761-9","article-title":"Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods","volume":"11","author":"Yoroidaka","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2025.09.014_bib0017","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.09.014_bib0018","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.09.014_bib0019","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cyto.a.24213","article-title":"OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood","volume":"97","author":"Park","year":"2020","journal-title":"Cytom Part A"},{"key":"10.1016\/j.clml.2025.09.014_bib0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cyto.a.24564","article-title":"OMIP-084: 28-color full spectrum flow cytometry panel for the comprehensive analysis of human \u03b3\u03b4 T cells","volume":"101","author":"Barros-Martins","year":"2022","journal-title":"Cytom Part A"},{"key":"10.1016\/j.clml.2025.09.014_bib0021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cyto.a.24702","article-title":"OMIP-086: full spectrum flow cytometry for high-dimensional immunophenotyping of mouse innate lymphoid cells","volume":"103","author":"Mincham","year":"2023","journal-title":"Cytom Part A"},{"key":"10.1016\/j.clml.2025.09.014_bib0022","article-title":"Ten color multiparameter flow cytometry in bone marrow and apheresis products for assessment and outcome prediction in multiple myeloma patients, front","volume":"11","author":"Riebl","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.clml.2025.09.014_bib0023","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3390\/cancers15072060","article-title":"Consensus for flow cytometry clinical report on multiple myeloma: a multicenter harmonization process merging laboratory experience and clinical needs","volume":"15","author":"Cordone","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.09.014_bib0024","first-page":"e352","article-title":"Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation","volume":"170","author":"Carulli","year":"2019","journal-title":"Clin Ter"},{"key":"10.1016\/j.clml.2025.09.014_bib0025","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-17-0012","article-title":"Clonal expansion and interrelatedness of distinct B-lineage compartments in multiple myeloma bone marrow","volume":"5","author":"Hansmann","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2025.09.014_bib0026","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","article-title":"Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system","volume":"107","author":"Dingli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.014_bib0027","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cyto.b.21371","article-title":"Stabilization of pre-optimized multicolor antibody cocktails for flow cytometry applications","volume":"92","author":"Chan","year":"2017","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2025.09.014_bib0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-1759(00)00226-X","article-title":"Validation and quality control of immunophenotyping in clinical flow cytometry","volume":"243","author":"Owens","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.clml.2025.09.014_bib0029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cyto.b.21615","article-title":"ICCS\/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 4 - assay validation and quality assurance","volume":"94","author":"Oldaker","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2025.09.014_bib0030","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/cyto.a.23781","article-title":"Stabilizing antibody cocktails for mass cytometry","volume":"Part A. 95","author":"Schulz","year":"2019","journal-title":"Cytom"},{"key":"10.1016\/j.clml.2025.09.014_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytom Part B Clin Cytom"},{"key":"10.1016\/j.clml.2025.09.014_bib0032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2025.09.014_bib0033","first-page":"1","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.09.014_bib0034","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/0113892010257212231001082741","article-title":"FDA-approved CAR T-cell therapy: a decade of progress and challenges","volume":"25","author":"Ong","year":"2023","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.clml.2025.09.014_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2025.09.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/232546","article-title":"Implications of heterogeneity in multiple myeloma","volume":"2014","author":"De Mel","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clml.2025.09.014_bib0037","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.014_bib0038","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.09.014_bib0039","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol Biomed"},{"key":"10.1016\/j.clml.2025.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/13543784.2020.1814253","article-title":"CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers","volume":"29","author":"Jiao","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2025.09.014_bib0041","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2024-204964","article-title":"Full spectrum multi-parameter single-tube flow cytometry analysis for cross-sectional immune-profiling of natural killer cells in multiple myeloma clinical samples","volume":"144","author":"Ray","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.014_bib0042","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-023-00851-5","article-title":"Mass cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma","volume":"13","author":"Baughn","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.09.014_bib0043","doi-asserted-by":"crossref","first-page":"47","DOI":"10.18632\/oncotarget.28350","article-title":"To be or not to be: the role of CD56 in multiple myeloma","volume":"14","author":"Cottini","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2025.09.014_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153567","article-title":"CD56 expression in multiple myeloma: correlation with poor prognostic markers but no effect on outcome","volume":"225","author":"Koumpis","year":"2021","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clml.2025.09.014_bib0045","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","article-title":"Redefining CD56 as a biomarker and therapeutic target in multiple myeloma","volume":"20","author":"Cottini","year":"2022","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clml.2025.09.014_bib0046","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.18632\/oncotarget.27190","article-title":"The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression","volume":"10","author":"Gilad","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2025.09.014_bib0047","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.3390\/jcm11102913","article-title":"CD24 is a prognostic marker for multiple myeloma progression and survival","volume":"11","author":"Even-Zohar","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2025.09.014_bib0048","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.09.014_bib0049","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2025.09.014_bib0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (VelcadeTM) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clml.2025.09.014_bib0051","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/leu.2012.42","article-title":"Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients","volume":"26","author":"Paiva","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.09.014_bib0052","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1172\/JCI128372","article-title":"BCMA CAR T cells: the winding path to success","volume":"129","author":"Borrello","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2025.09.014_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1398902","article-title":"Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma","volume":"14","author":"Miller","year":"2024","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.09.014_bib0054","first-page":"1","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"141","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.09.014_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers13010017","article-title":"High-dimensional analysis of single-cell flow cytometry data predicts relapse in childhood acute lymphoblastic leukaemia","volume":"13","author":"Chuli\u00e1n","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.clml.2025.09.014_bib0056","first-page":"1","article-title":"The art of using t-SNE for single-cell transcriptomics","volume":"101","author":"Kobak","year":"2019","journal-title":"Nat Commun"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:06:59Z","timestamp":1773277619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025042259"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced Multicolor Flow Cytometry Method for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}